Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
1. Olema initiates a Phase 1b/2 study of palazestrant-atirmociclib combination. 2. Collaboration with Pfizer aims at ER+/HER2- metastatic breast cancer treatment. 3. Palazestrant is positioned to revolutionize metastatic breast cancer therapies. 4. Research may lead to pivotal Phase 3 trial outcomes and fast-track designation. 5. Olema retains full global commercial rights for palazestrant despite joint data ownership.